The ongoing clinical trials and regulatory reviews signal a wave of new therapies that will continue to transform weight management
Therefore, addressing the challenges associated with the long-term administration of peptide hormones is crucial [19, 20]
2022 Feb 25;13(1):1057
Recently, potent incretin mimetics, including semaglutide (a GLP1 receptor agonist) and tirzepatide (a dual GLP1 and GIP receptor agonist), have become widely available for patients with obesity or who have overweight and have a cardiovascular risk factor
Choose Injections If: You want a proven, fully licensed UK weight loss option, prefer only thinking about your medication once a week, and are comfortable using a tiny needle
Food is more than just sustenance, its mood, social, celebration and culture